Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 5/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19380241 | 0.87 | ALDH1A1 (0.69) | ALDH1A1HPGDKDM4CMAPTGAA | |
| SCHEMBL10288646 | 0.87 | ALDH1A1 (0.74) | ALDH1A1HPGDKDM4CMAPTGAA | |
| SCHEMBL10243011 | 0.84 | ALDH1A1 (0.70) | ALDH1A1HPGDKDM4CMAPTGAA | |
| SCHEMBL13073430 | 0.84 | MEN1 (0.74) | ALDH1A1HPGDKDM4CMAPTGAA | |
| SCHEMBL16492626 | 0.84 | ALDH1A1 (0.66) | ALDH1A1HPGDKDM4CMAPTGAA | |
| SCHEMBL1742676 | 0.83 | KDM4C (0.69) | ALDH1A1HPGDKDM4CMAPTGAA | |
| SCHEMBL22819412 | 0.83 | KDM4C (0.69) | ALDH1A1HPGDKDM4CMAPTGAA | |
| SCHEMBL28514763 | 0.83 | ALDH1A1 (0.68) | ALDH1A1HPGDKDM4CMAPTGAA | |
| SCHEMBL9796585 | 0.82 | ALDH1A1 (0.67) | ALDH1A1HPGDKDM4CMAPTGAA | |
| SCHEMBL31047592 | 0.82 | ALDH1A1 (0.67) | ALDH1A1HPGDKDM4CMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263774-B2 | Quinoline-oxazoline compounds and their use in oxidation synthesis | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263774-B2 | Quinoline-oxazoline compounds and their use in oxidation synthesis | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-09-11 | — | — | US | disclosed |
| US-20110054176-A1 | QUINOLINE-OXAZOLINE COMPOUNDS AND THEIR USE IN OXIDATION SYNTHESIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-03 | — | — | US | disclosed |
| US-20110054176-A1 | QUINOLINE-OXAZOLINE COMPOUNDS AND THEIR USE IN OXIDATION SYNTHESIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-03 | — | — | US | disclosed |
| US-7470794-B2 | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors | WYETH (US) | 2008-12-30 | — | — | US | disclosed |
| US-20050085504-A1 | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors | WYETH (US) | 2005-04-21 | — | — | US | disclosed |
| US-6825352-B2 | ANTIARTHRITIC, ANTITUMOR, ANTIMETASTASIS, ANTIULCER, AND WOUND HEALING AGENTS; BONE, NERVOUS SYSTEM, DEGENERATIVE JOINT DISORDERS; PROTEINURIA, ANEURYSMS, HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTIONS | WYETH | 2004-11-30 | — | — | US | disclosed |
| CN-1411446-A | Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors | WYETH CORP (US) | 2003-04-16 | — | — | CN | disclosed |
| US-20030035332-A1 | The preparation and use of ortho-sulfonamido arylhydroxamic acids as matrix metalloproteinase inhibitors | WYETH | 2003-02-20 | — | — | US | disclosed |
| EP-1259488-A1 | ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE INHIBITORS | Wyeth (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20020169184-A1 | PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-11-14 | — | — | US | disclosed |
| US-6465508-B1 | NONPEPTIDE INHIBITORS OF GELATINASES, STROMELYSINS AND COLLA-GENASES; ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, PROTEINURIA, ANEURYSMAL AORTIC DISEASE, HIV | WYETH | 2002-10-15 | — | — | US | disclosed |
| WO-2001062733-A1 | ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054176-A1 | QUINOLINE-OXAZOLINE COMPOUNDS AND THEIR USE IN OXIDATION SYNTHESIS | XDH, OXA1L, AOX1 | ALDH1A1 421/4885HPGD 396/4885KDM4C 756/4885 |
| US-20020169184-A1 | PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | MMP1, MMP7, MMP2 | ALDH1A1 1377/4885HPGD 239/4885KDM4C 3268/4885 |
| US-20050085504-A1 | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors | MMP1, MMP7, MMP2 | ALDH1A1 1377/4885HPGD 239/4885KDM4C 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.